An overview of Hedgehog signaling in fibrosis

Liping Hu, Xiangyang Lin, Hong Lu, Bicheng Chen, Yongheng Bai

Department of Laboratory Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China (LH, XL, HL)

Department of Laboratory Medicine, JianLi County People's Hospital, Jingzhou, China (LH)

Wenzhou Key Laboratory of Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China (BC, YB)

MOL #95141

RUNNING TITLE PAGE

Running title: Hedgehog signaling in fibrosis

Corresponding authors:

Yongheng Bai MD,

Wenzhou Key Laboratory of Surgery, The First Affiliated Hospital, Wenzhou Medical

University, 2# Fuxue Lane, Wenzhou 325000, China;

Phone: +86-577-55579722; E-mail: baiyongheng@hotmail.com

Number of text pages: 22

Number of tables: 0

Number of figures: 3

Number of references: 141

Number of words in Abstract: 120

Number of words in main text: 4862

List of abbreviations used in the paper:

BDL: bile duct-ligated; Dhh: Desert hedgehog; ECM: extracellular matrix; EMT: epithelial-mesenchymal transition; HSC: hepatic stellate cell; Ihh: Indian hedgehog; IPF: idiopathic pulmonary fibrosis; NASH: non-alcoholic steatohepatitis; NKT: natural killer T; OPN: osteopontin; PDGF: platelet derived growth factor; Shh: Sonic hedgehog; TGF-β: transforming growth factor-β

ABSTRACT

The Hedgehog (Hh) signaling pathway plays a key role during embryogenesis and tissue regeneration. Recently, studies revealed that over-activated Hh signaling leads to fibrogenesis in many types of tissues. The activation of Hh signaling is involved in epithelial-mesenchymal transition (EMT) and excessive extracellular matrix deposition. Blockade of Hh signaling abolishes the induction of EMT and ameliorates tissue fibrosis. Therefore, new therapeutic targets to alleviate fibrosis based on the Hh signaling have attracted a great deal of attention. This is a new strategy for treating fibrosis and other related diseases. In this review, we will discuss the crucial role of Hh signaling in fibrogenesis to provide a better understanding of their relationship and to encourage the study of novel targeted therapies.

INTRODUCTION

In fibrosis, tissue parenchyma cell necrosis is caused by sustained inflammatory stimulation and is a pathological process with enhanced production and excessive deposition of extracellular matrix (ECM). Fibrosis is a repairing process and also induces sclerosis and tissue hypofunction when the injury is persistent or the repair process is not sufficient. Tissue fibrosis is the common final outcome of a wide variety of chronic diseases, regardless of the initial causes (Liu, 2006; Boor et al., 2010; Zeisberg and Neilson, 2010). It is known that some signaling pathways have an important role in the occurrence and development of tissue fibrosis, such as Wnt/β-catenin (He et al., 2009), Notch (Bielesz et al., 2010) , Ras-Raf-Mek (Grande et al., 2009), and the PI3K/Akt pathway (Niu et al., 2007). Recently, evidence suggests that the Hedgehog (Hh) signaling pathway may be involved in fibrogenesis in multiple tissues (Omenetti et al., 2007; Jung et al, 2011; Fabian et al., 2012).

The Hh signaling was first discovered in the *Drosophila* fruit fly (Nusslein-Volhard and Wieschaus, 1980). In mammals, the Hh signaling plays a crucial role in embryonic development and differentiation and proliferation in brains and spinal cords, as well as in the pattern of internal organs and limbs, such that the developing tissues are the correct size with the appropriate cell types and degrees of innervation and vascularization. Additionally, evidences also showed that Hh signaling has a pivotal role in maintaining the number of tissue stem cells (BeachyPhilip et al., 2004). Furthermore, the Hh signaling regulates body height and aging and the associated

inflammatory and chronic degenerative diseases (Weedon et al., 2008; Neureiter, 2012; Dashti et al., 2012). Deactivation of this signaling may result in hereditary developmental defects, such as holoprosencephaly, whereas over-activation of this signaling by mutations may lead to many tumors, such as prostate cancer (Xie, 2005), pancreatic cancer (Hidalgo and Maitra, 2009), and basal cell carcinoma (Xie, 2008). Moreover, activated Hh signaling is also involved in fibrogenesis of many tissues, such as liver fibrosis, pulmonary fibrosis, and renal fibrosis (Sicklick et al, 2005; Bolanos et al., 2012; Fabian et al., 2012). In this study, we provide an overview of the Hh signaling and discuss its role in the occurrence and development of tissue fibrosis.

HH SIGNALING PATHWAY

In mammals, there are three Hh homologs with different spatial and temporal distribution patterns: Desert hedgehog (Dhh), Indian hedgehog (Ihh), and Sonic hedgehog (Shh) (Krauss et al., 1993; Riddle et al., 1993; Roelink et al., 1994). These palmitoyl- and cholesterol-modified proteins are expressed by a number of different types of cell, and have functional specificity that is governed in part by their regulatory mechanisms and expression patterns in a given cell type (Pathi, 2001).

The Hh signaling pathway includes two transmembrane proteins, namely Patched (Ptch), a 12-transmembrane protein, and Smoothened (Smo), a 7-transmembrane protein with a topology reminiscent of G-protein-coupled receptors, which acts as a signal transducer (Murone et al., 1999). In mammals, two isoforms of Ptch are

encoded by Ptch1 and Ptch2. Ptch1 is the only isoform definitively involved in the activation of Hh signaling, which is confined to target cells and is up-regulated in response to the Hh proteins. Ptch2 is co-expressed with Hh proteins, but its transcription is independent of pathway activation (St-Jacques et al., 1998). Goodrich and colleagues found that the inhibition of Smo activity was abolished in Ptch1 knock-out mice (Goodrich et al., 1997). In vivo, the Smo protein exists in either an inactive or active state that appears to be defined, in addition to other modifications, by its location within the cells, either inside or outside the primary cilium (Corbit et al., 2005). The primary cilium has a microtubule-based antenna-like structure which originates from the surface of most of mammalian cells (Drummond, 2012).

The Ptch protein localizes to the primary cilium and suppresses Smo activity when the Hh ligands are absent. Here, only the Gli repressor forms are able to enter the nucleus. Binding of the Hh ligands to the Ptch protein shuttles Ptch out of the cilium, resulting in the release and activation of Smo, and then the Gli protein can translocate the nucleus and function as a transcriptional activator (Gill PS, 2006; Varjosalo and Taipale, 2008; Choy and Cheng, 2012) (Figure 1).

Gli proteins belong to the Kruppel-like family of transcription factors with highly conserved zinc finger DNA-binding domains. There are three Gli proteins in mammals, namely Gli1, Gli2, and Gli3, and each is encoded by distinct genes. By contrast, their homolog Cubitus interruptus in *Drosophila* is unique (Kasper et al.,

2006; Hui and Angers, 2011). In vivo, different type of Gli proteins exhibits distinct

regulation, biochemical properties and target genes. Abnormal expression of Gli1 or a

dominant-active mutant form of Gli2 in keratinocytes regulates both the overlapping

and distinct transcriptional programs for these two proteins (Eichberger et al., 2006).

For example, whereas both Gli1 and Gli2 induce Ptch1 and Tenascin-C, Gli1

exclusively regulates vestigial like 4, and lipopolysaccharide-induced TNF factor is a

specific target of Gli2. Other studies have identified MUC5A (Inaguma et al., 2011)

and osteopontin (OPN) (Das et al., 2009) as Gli1 targets, whereas functional binding

sites of Gli2 have been characterized on Bcl-2 (Regl, 2004), Follistatin (Eichberger et

al., 2008), PTHrP (Sterling et al., 2006), and BMP-2 (Zhao et al., 2006) promoters.

In addition to the previously described "canonical" Hh pathway, there are several Hh

signaling pathways that do not signal through Gli or Smo. These are named the

"noncanonical" Hh signaling pathways (Jenkins, 2009). Currently, evidence suggests

that there are at least two distinct classes of noncanonical Hh signaling (Figure 2), and

these two noncanonical Hh signaling pathways may lead to various physiological

functions in different types of tissues.

Type I noncanonical signaling works through functions of Ptch1 that are unrelated to

its inhibitory activity on Smo (Pola et al., 2001; Lavine et al., 2008; Chinchilla et al.,

2010; Brennan et al., 2012). Knockdown of Ptch1 gene by siRNA in endothelial cells

enhances cell survival, but it is lack of detectable canonical signaling in endothelial

cells both in vitro and in vivo (Lavine et al., 2008; Chinchilla et al., 2010). In addition, the Smo antagonists cyclopamine and SANT-1 can not mimic Shh-mediated anti-apoptotic effect (Chinchilla et al., 2010). Furthermore, Ptch1 regulates cell cycle through Cyclin B1 in a Smo- and Gli-independent manner (Barnes et al., 2001; Jenkins, 2009). Thus, these findings support that notion that Type I noncanonical signaling is a pathway engaged exclusively by Ptch1.

Type II noncanonical signaling operates via Smo functions beyond Gli regulation (Chinchilla et al., 2010; Polizio et al., 2011; Brennan et al., 2012). Recent studies showed that Smo-dependent signaling is mediated through the activation of small GTPases (Polizio et al., 2011). Another recent study, by xx and colleagues, suggested that Shh-induced fibroblast migration is Smo-dependent but Gli-independent (Bijlsma et al., 2007). Thus, Type II noncanonical signaling is a pathway engaged by Smo.

HH SIGNALING AND LIVER FIBROSIS

Cirrhosis is regarded as a lethal end point of a large number of chronic liver diseases, such as obesity-related liver disease and chronic viral hepatitis (Pinzani et al., 2011). When regenerative processes fail to keep pace with hepatic cell death, cirrhosis of liver develops and results in the progressive replacement of functional epithelial cells with scar tissue (Wells, 2008; Lee and Friedman, 2011). As a hallmark of cirrhosis, liver fibrosis is hypothesized to drive the changes in liver function and blood flow that cause liver-related morbidity and mortality (Wells, 2008; Hernandez-Gea and

Friedman, 2011).

In general, Hh ligands are not expressed in healthy liver tissue, and Hh signaling is not activated either in mature cholangiocytes or in hepatocytes (Omenetti et al., 2007; Yang L, 2008; Choi et al., 2009). However, these two types of mature epithelial cells start to secrete Hh ligands when subjected to certain injury-associated cytokines or lethal stresses (Jung et al., 2010; Omenetti and Diehl, 2011). The Hh ligands diffuse away from the wounded epithelial cells and enter the bile canaliculi and hepatic sinusoids to stimulate viable Hh-responsive cells that line these structures. Hepatic stellate cell (HSC) is a kind of Hh-responsive cell in the space of Disse and progenitors along the canals of Hering. Activated Hh signaling induces the HSCs to differentiate into fibrogenic myofibroblasts. In turn, both liver progenitors and myofibroblasts derived from HSC also can secrete Hh ligands, and then further enrich the injured microenvironment with these factors (Omenetti and Diehl, 2011). However, not all Hh-pathway activation promotes cirrhosis, but sustained or excessive Hh signaling does (Ochoa et al., 2010).

Recently, it has been demonstrated that the activation of Hh signaling can promote liver fibrosis. In mice (Fleig et al., 2007; Syn et al., 2009) and humans (Syn et al., 2009), hepatic activation of Hh signaling strongly correlates with the fibrogenic progress and the severity of liver injury. Furthermore, activated Hh signaling can promote liver fibrosis by combining with other cells and factors. In rodents and

humans with non-alcoholic steatohepatitis (NASH), Hh signaling activation leads to the recruitment, retention and viability of natural killer T (NKT) cells. In turn, NKT cells induce the production of Hh ligands that trigger liver fibrosis (Syn et al., 2009; Syn et al., 2010; Syn et al., 2012). For example, more NKT cells are accumulated in the Ptch knock-out mice and thereby developed worse hepatic fibrosis. CD1d-deficient mice, which lack NKT cells, were protected from fibrogenesis (Syn et al., 2010), and NASH-related cirrhosis was prevented by NKT cell depletion in rodents (Syn et al., 2010). Tissue expression of the NKT cell chemoattractant CXCL16, an Hh-inducible gene, and hepatic expression of IL-15 and Cd1d, which are the three factors that increase NKT cell viability, are significantly up-regulated in mice with enhanced Hh signaling activity and NASH-related fibrosis (Omenetti et al., 2009; Tajiri et al., 2009). Moreover, the Shh protein induces NKT cells to release profibrogenic cytokines, such as IL-13 and IL-4, which play pivotal roles in liver fibrosis (Chiaramonte MG, 1999; Fichtner-Feigl et al., 2006; Syn et al., 2009). Additionally, Diao and several other researchers demonstrated that liver NKT cells can produce OPN, a Hh-regulated cytokine, which acts in both an autocrine and paracrine manner, to induce HSC activation and liver fibrosis, suggesting that OPN mediated directly the fibrogenic actions of NKT cells (Diao et al., 2004; Syn et al., 2009; Choi et al., 2009). Similarly, high plasma levels of OPN may be predictive of cirrhosis in patients with chronic hepatitis B and C (Zhao et al., 2008; Huang et al., 2010).

In addition, leptin is another factor that activates Hh signaling to regulate gene expression programs that control cell fate and has important implications for hepatic fibrosis (Choi et al., 2010). First, leptin increases the expression of snail mRNA in HSCs, and this response is blocked by inhibitors of PI3K and Akt and cyclopamine (Saxena et al., 2004; Niu et al., 2007; De Minicis et al., 2008). Snail is a transcription factor that exhibits a major role in the EMT, and many conditions that promote the EMT induce the expression of snail mRNAs (Li X, 2006). Second, the interaction between leptin and ObRb (a leptin receptor) activates Hh signaling, resulting in the mesenchymal transition in HSCs. Hh signaling activation is required for the transition of epithelioid quiescent HSCs into HSC-derived myofibroblasts and liver fibrosis (Yang L, 2008; Choi et al., 2010; Michelotti et al., 2013). Other factors that regulate the trans-differentiation and growth of HSC-derived myofibroblasts, such as transforming growth factor-β (TGF-β) and platelet derived growth factor (PDGF), also activate and depend upon Hh signaling for their fibrogenic actions (Yang L, 2008; Jung et al., 2008; Philips et al., 2011).

Chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is a major cause of cirrhosis and liver cancer worldwide (Caldwell and Park, 2009; Fung J, 2009). Pereira and colleagues showed that virus hepatitis significantly increased the expression of the Hh-ligands Ihh and Shh and target genes Ptch and Gli2. They also showed that patients with more advanced stages of liver diseases (i.e., bridging fibrosis to cirrhosis) expressed higher levels of Shh, Ptch and Gli2 than those with

little or no fibrosis (Pereira Tde et al., 2010). These findings explain why many individuals who are infected with HBV or HCV do not develop significant liver fibrosis or neoplasia.

EMT is necessary for tissue fibrosis, and TGF-β is the most established mediator of EMT (Zeisberg et al., 2003; Thiery et al., 2009). TGF-β induced hepatocyte EMT has been confirmed in mouse experiments (Kaimori et al., 2007). The ability of Hh-ligands to promote EMT has been demonstrated in various tissues, including the liver (Choi et al., 2009; Syn et al., 2009), bile duct (Omenetti et al., 2008) and others. Previously, it had been verified that Hh-signaling regulates EMT during development (Hay, 1995; Bailey et al., 2007). These results suggest that Hh-related EMT may depend, at least partially, on the induction of TGF-β (Wang et al., 2012).

Recently, several small-molecule inhibitors of Hh pathway have been used in treating liver fibrosis. As described in the Journal by Syn et al., Smo antagonist cyclopamine attenuates EMT-associated fibrogenesis in rats with nonalcoholic fatty liver disease (NAFLD) (Syn et al., 2009) and reverted myofibroblastic transition in vitro (Choi et al., 2009). Another recent study, by Philips and colleagues, suggests that treatment with GDC-0449, another small-molecule inhibitor that binds to Smo, significantly decreased liver myofibroblasts and progenitors and reduced liver fibrosis without increasing mortality (Philips et al., 2011). In addition, vismodegib (GDC-0449) also can effectively attenuate early liver fibrosis by suppressing Hh signaling (Pratap et al.,

2012). These evidences supported that pharmacologic inhibition of hedgehog signaling may have therapeutic potential for liver fibrosis.

HH SIGNALING AND BILE DUCT FIBROSIS

Fibrosis is the common pathological process of chronic biliary injury in both rodents and humans (Lazaridis et al., 2004). Rygiel and Robertson showed that EMT might have an important role in the pathogenesis of biliary fibrosis because there is high expression of vimentin and other mesenchymal markers in proliferating bile ductules within fibrotic portal tracts in liver tissues from patients with primary biliary cirrhosis (PBC) as demonstrated by immunostaining (Rygiel et al., 2008). Omenetti and colleagues showed that activated Hh signaling induces EMT in adult bile ductular cells by studying liver tissues from rats and patients with biliary fibrosis and manipulating Hh signaling activity in primary cholangiocyte cells, cholangiocytes, and mice subjected to biliary injury (Omenetti et al., 2008). They also demonstrated Hh ligands accumulation and Hh-signaling activation in the liver tissues of patients with PBC (Jung et al., 2007) and bile duct-ligated (BDL) rodents (Omenetti et al., 2007). In vivo, a similar process likely regulates EMT because changes in gene expression associated with EMT and liver fibrogenesis were amplified after BDL in Ptch knock-out mice, which have an impaired ability to turn off Hh signaling after biliary injury (Omenetti et al., 2008). In addition to these observations, Hh may promote EMT crosstalk with TGF-β via both the canonical Hh pathway (Huber et al., 2005) and noncanonical Hh pathway (Lauth and Toftgard,

2007).

The types of cells in the biliary tract that produce Hh and other ligands remain unknown. Immunohistochemical analysis demonstrated that ductular cells can induce the production of Hh ligands Shh and Ihh in diseased and healthy liver samples from adults and children. The production of Hh ligands is induced by various biliary stressors, including viral infection, immune-mediated biliary attack, mechanical obstruction of BDL, and various genetic disorders that interfere with biliary transport (e.g., PFIC-1, PFIC-2) (Jung et al., 2007; Omenetti et al., 2007). Hh ligands can also be produced by ductular-appearing cells when hepatocyte injury is induced by viral infection (Pereira Tde et al., 2010), nutritional factors (Syn et al., 2009; Jung and Diehl, 2010, Syn et al., 2010; Syn et al., 2011) or toxins (Jung et al., 2008; Jung et al., 2010). Mature cholangiocytes, such as murine 603B and rat cholangiocytes NRC1, and primary cholangiocytes isolated from healthy adult rodents have been identified to express mRNA and proteins of Hh ligands indicated by real-time PCR and western blot/immunocytochemistry, respectively (Omenetti et al., 2007; Omenetti et al., 2008). Moreover, these cells release active Hh ligands that can activate Hh signaling in some neighboring cells that have been transfected stably with Gli-luciferase reporter constructs (Witek et al., 2009).

The mechanisms regulating Hh ligand production by these cells are not clear yet. In vitro, exogenous PDGF-BB-induced activation of cholangiocyte promotes exosomes

production. These exosomes contain biologically active Shh and Ihh ligands, and stimulate biliary cells to start Hh signaling in adjacent hepatocytes through paracrine pathway (Witek et al., 2009). The significant enrichment of membrane-associated Hh ligands in the bile occurs after an injury, such as BDL, which activates cholangiocytes in situ (Witek et al., 2009), increasing the possibility that such liver-derived Hh ligands may also activate Hh signaling in Hh-responsive cells that reside in other tissues immediately "down-stream" of the biliary or hepatic venous outflow, such as the heart or intestine. In activated hepatic stellate cells and cholangiocytes (Yang L, 2008), PDGF-BB is produced and then induces the expression of Shh and inhibitors of AKT and/or PI3K that act down-stream of PDGF-BB to suppress this process (Omenetti et al., 2008). In some types of liver injury, myofibroblasts localize near ductular type cells, and release some soluble factors that trigger Hh signaling in ductular cells. Thus, paracrine mechanisms may also increase the expression of Hh target genes in cholangiocytes. Evidence from antibody neutralization experiments indicates that some factors from myofibroblasts including Shh and TGF-β may also be involved (Omenetti et al., 2007; Omenetti et al., 2008).

HH SIGNALING AND RENAL FIBROSIS

Renal tubulointerstitial fibrosis, a process often considered a result failed to wound repair after injury (Zeisberg and Neilson, 2010), is the common outcome of an wide variety of progressive chronic kidney diseases (CKD) (Liu, 2006; Boor et al., 2010; Zeisberg and Neilson, 2010). There is growing evidence that the aberrant activation

and dysregulation of key development-associated signaling may play an important role in the pathogenesis of chronic tissue destruction and impaired renal function (Surendran et al., 2005; He et al., 2009). Because of the importance of Hh signaling in nephron formation and kidney development (Yu J, 2002; Cain and Rosenblum, 2010), some researchers hypothesize that the abnormal activation of this signaling pathway most likely results in renal fibrosis (Ding et al., 2012; Fabian et al., 2012).

Fabian and his group (Fabian et al., 2012) confirmed that during renal fibrosis, Ihh induction promotes Ptch1 and Gli1 expression in the kidney cortex and medulla, particularly in the adjacent tubular epithelium, and that the induction of Gli1 was completely suppressed by the Smo antagonist IPI-926. The epithelial localization of both Ihh and Shh in the kidney, combined with the stromal expression of Gli1 and Gli2 in the renal interstitium, suggesting that Hh acts in a paracrine manner during renal fibrosis, similar to its role during renal development (Yu J, 2002; Cain et al., 2009). Hh signaling also induces the activation of myofibroblast and production of ECM by directly regulating the expression of a series of fibrogenic genes, such as Gli1, Snail1 (Thiery, 2003; Rowe et al., 2009), type I collagen, fibronectin, desmin, and a-SMA, leading to increased ECM deposition and scar formation (Ding et al., 2012).

In addition, the Hh pathway may promote renal fibrosis by acting in combination with other signaling pathways. For example, Hh signaling up-regulates Wnt-2b and Wnt-5a

and the Notch ligand Jaggad-2 (Katoh and Katoh, 2008; Katoh and Katoh, 2009), and both Hh signaling and Wnt/β-catenin is able to increase Snail1 expression (Dai et al., 2009), the combination of which can accelerate the progression of several diseases, including tissue fibrosis and cancer. Activated Hh signaling may trigger renal fibrosis by regulating other fibrogenic signaling such as PI3K/AKT pathway. In turn, both the RAS-RAF-MEK and PI3K/AKT pathways can potentiate Gli1 function or activate Gli signaling independent of Smo (Pasca di Magliano et al., 2006; Ji et al., 2007; Stecca and Ruiz, 2010), and both pathways are implicated in renal myofibroblast activation (Rodriguez-Pena et al., 2008; Bechtel et al., 2010; Grande et al., 2010). TGF-β, which has a critical role in renal fibrosis (Bottinger, 2002), can also activate Gli2 expression independent of Ptch1/Smo in human fibroblasts (Dennler et al., 2007).

The important role of Hh signaling in renal fibrosis is also demonstrated by the therapeutic efficacy of its inhibitors. Cyclopamine, a small molecule inhibitor of Smo, inhibits the activation of fibroblast and production of ECM in vitro and attenuates renal fibrosis in vivo in an obstructive nephropathy model. Intriguingly, the expression level of Shh is not affected, but the induction of Gli1 and Snail1 downstream is largely inhibited by cyclopamine. These results are consistent with the ability of Shh to antagonize Smo activity. Notably, the ameliorative effect of cyclopamine shows greater than that of Gli1 deficiency, and this indicates that Gli1 may not be the only mediator of Hh signaling during obstruction-induced renal fibrogenesis (Ding et al., 2012). Another finding shows that the Smo inhibitor

suppressed Gli1 induction and did not inhibit Gli2 induction, indicating that Gli2 may be the more important effector in renal fibrosis (Fabian et al., 2012). Additional studies are necessary to understand the signaling pathway.

HH SIGNALING AND PULMONARY FIBROSIS

Pulmonary fibrosis is a pathological condition associated with chronic airway inflammation. Architectural remodeling and the fibrosis of tissues can severely damage lung function, resulting in worst outcome. Remodeling interacts among several cell types, including endothelial cells, epithelial cells, fibroblasts, and both recruited and resident cells of the immune system (Stewart et al., 2003). When the remodeling process fails to repair the tissue, fibrosis develops with the formation of scar tissue (Kasper and Haroske, 1996). Several airway structural cells, including epithelial cells, endothelial cells, and pericytes, contribute to pulmonary fibrosis through a process of molecular reprogramming, mediated by proteins such as Shh (Stewart et al., 2003) and TGF-β (Khalil et al., 1996; Levine et al., 2000).

Shh, which is critical for the normal development of the lungs via its interactions with its receptor Ptch1, activates the Gli family of transcription factors (Motoyama et al., 1998; Pepicelli et al., 1998). Moreover, the paracrine signaling of Shh specifically contributes to branch morphogenesis in the embryonic lung (Bellusci, 1997). During the branching morphogenesis of the lung, Shh is produced by the endoderm and stimulates mesenchymal cellular proliferation and differentiation, as evidenced by the

observation that over-expression of Shh leads to an aberrant increase of the lung

mesenchyme (Weaver et al., 2003). These observations raise the possibility that the

Hh signaling pathway participates in pulmonary fibrosis. In a model of

bleomycin-induced adult lung injury, there are abundant Gli1-positive cells in the

preserved alveolar septa and increased numbers of Gli1-positive mesenchymal cells in

fibrotic lesions, and adenovirus-mediated over-expression of Shh enhances ECM

production (Liu et al., 2013). Another study, by Stewart and colleagues, indentified

over-expression of Shh in the lung epithelium in human idiopathic pulmonary fibrosis

(IPF) and murine lung inflammation and FITC-induced fibrosis (Stewart et al., 2003).

Using in situ hybridization, Coon and colleagues showed that Shh is high-expressed

in the epithelium of cysts within the IPF lung (Stewart et al., 2003; Coon et al., 2006).

Recently, Lozano-Bolanos and colleagues found that in human IPF the Hh pathway is

activated (Bolanos et al., 2012). They also provided extensive in vitro data indicating

that Shh increases the migration, proliferation, and survival of fibroblasts, and the

production of ECM, which is also demonstrated by the observation that Hh signaling

increases ECM production and triggers the fibroblast-to-myofibroblast transformation

(Horn et al., 2012).

Furthermore, Stewart et al., (Stewart et al., 2003) detected the Shh receptor Ptch in

normal resting peripheral blood T lymphocytes and infiltrating mononuclear cells and

alveolar macrophages. In patients with interstitial lung disease, this remodeling is

continuous and results in lung fibrosis accompanied by a predominantly mononuclear

lymphoid infiltrate in which both B and T lymphocytes are present (Tuder, 1996; Lympany and du Bois, 1997). Katoh (Katoh, 2004) and Tseng (Tseng et al., 2004) found that FOXF1 is a downstream target of Shh in the lung, a target for Gli2/3 proteins activated by Shh (Motoyama et al., 1998). However, the expression level of Shh and FOXF1 in lungs with usual interstitial pneumonitis and nonspecific interstitial pneumonitis was differential. It is postulated that the pathogenic pathways of interstitial pneumonitis may include a defect in Hh signaling, thereby activating FOXF1 (Coon et al., 2006). These findings demonstrate that Hh signaling promotes pulmonary fibrosis through contact with other various types of factors. Therefore, it is useful to thoroughly study the pathway in pulmonary fibrosis and other tissue fibrosis.

HH SIGNALING AND OTHER TISSUE FIRBOSIS

In addition to the types of fibrosis described above, there are other types of fibrosis, such as pancreatic fibrosis (Jung et al., 2011) and cardiac fibrosis (Bijlsma et al., 2008), which are also closely related to Hh signaling pathway.

In a study by Bijlsma (Bijlsma et al., 2008), endogenous Shh protein was shown to contribute to ischemia-reperfusion-induced injury, and cyclopamine treatment reduced this myocardial ischemia-reperfusion-induced injury. However, several studies have suggested that the Shh protein may exert beneficial effects. As described by Kusano et al., intramyocardial gene transfer of naked DNA encoding human Shh promotes the recovery and preservation of left ventricular function in both acute and chronic

myocardial ischemia models (Kusano et al., 2005). Shh has considerable therapeutic potential in patients with acute and chronic myocardial ischemia by enhancing neovascularization, recruiting bone marrow-derived progenitor cells, and reducing cardiac apoptosis and fibrosis (Kusano et al., 2005). Hh signaling also exhibits an important role in adult cardiovascular pathophysiology. The Shh protein up-regulates markedly the expression of Hh target genes, such as vascular endothelial growth factor and the angiopoietins Ang-1 and Ang-2, which can induce neovascularization (Pola et al., 2001). Based on these observations, we speculate that the Hh signaling may play a discriminatory role in different types of tissues or during different phases of disease development and the latter could be assessed at different time points. Therefore, the activation of Hh signaling appears to exert a dualistic effect in cardiac ischemia in which high exogenous levels of Shh can foster tissue repair and endogenous Hh protein may aggravate ischemic diseases.

In pancreatic tissues, Hh signaling is strictly controlled. Quiescent Hh signaling is a key event for proper pancreatic differentiation and development. However, in fibrogenic pancreatic diseases the signaling is frequently reactivated. An in vitro study revealed that exogenous Ihh protein enhanced the migrational ability of pancreatic stellate cells (Shinozaki et al., 2008). These stellate cells locating in the vicinity of the acini are the main source of proliferating fibroblasts in human diseases. Another recent observation showed that over-expression of Smo in pancreatic cancer-associated fibroblasts is a potential determinant for Hh-responsiveness (Walter

et al., 2010). Jung (Jung et al., 2011) provides in vivo evidence that secreted Hh

ligands induce pancreatic fibrosis by activating responsive cells in a paracrine fashion.

They identified TGF-β and MMPs as important mediators of Hh signaling, which is

consistent with the observations that TGF-β cooperates with canonical Hh signaling to

regulate the expression of Gli proteins and Hh target gene (Karhadkar et al., 2004;

Dennler et al., 2007) and that in cultured pancreatic cells exogenous Hh molecules or

ectopic expression of Gli1 or Hh molecules promotes the expression of MT1-MMP

and MMP9 (Nagai et al., 2008; Liao et al., 2009).

PERSPECTIVES

Tissue fibrosis is a physiological and pathological process in many diseases. In

fibrogenesis, Hh signaling plays a crucial role and its targeted interference exerts

anti-fibrotic effects to some extent. Therefore, Hh signaling transduction and its

regulatory factors is a promising field because Hh signaling may be a therapeutic

target for disease treatment (Figure 3).

Cyclopamine is an alkaloid that specifically inhibits the activity of the Hh receptor,

Smo (Incardona et al., 2000; Chen et al., 2002). It has been reported that in liver

(Pratap et al., 2011) and cardiac diseases (Bijlsma et al., 2008), cyclopamine can

reduce injury and fibrosis. An in vivo study demonstrated that inhibition of Smo by

LDE223, or transfection with siRNAs against Smo attenuates experimental fibrosis

and induces the regression of established fibrosis (Horn et al., 2012). GANT61, an

inhibitor of Gli transcription factors in the nucleus, can decrease pulmonary fibrosis and collagen accumulation and promote an anti-fibrotic and anti-inflammatory environment in a bleomycin-induced lung injury model in mice (Moshai et al., 2014). Thus, new therapeutic targets must be identified in the Hh signaling pathway to treat tissue fibrosis. This will lead to new strategies for treating tissue fibrosis and other related diseases. However, in some types of tissues, the blockade of Hh signaling does not reduce fibrosis. A study by Kusano and colleagues suggests that activated Hh signaling by exogenous Hh also exerts a beneficial effect by increasing neovascularization, recruiting bone marrow-derived progenitor cells, and reducing cardiac apoptosis and fibrosis (Kusano et al., 2005). Under such circumstances, inhibiting the Hh pathway may not be ideal for attenuating fibrosis. Therefore, the different roles of Hh signaling in different types of tissue fibrosis should be ascertained. Similarly, appropriate and effective therapies based on Hh signaling are also necessary.

MOL #95141

COMPETING INTERESTS

All authors declare that there are no competing financial interests.

ACKNOWLEDGEMENTS

None.

AUTHORSHIP CONTRIBUTIONS

Participated in research design: Hu, Lin, and Bai.

Conducted experiments: not applicable.

Contributed new reagents or analytic tools: not applicable.

Performed data analysis: not applicable.

Wrote or contributed to the writing of the manuscript: Hu, Lu, Chen, and Bai.

REFERENCES

Bailey JM, Singh PK and Hollingsworth MA (2007) Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. *J Cell Biochem* **102**(4):829-839.

Barnes EA, Kong M, Ollendorff V and Donoghue DJ (2001) Patched1 interacts with cyclin B1 to regulate cell cycle progression. *EMBO J* **20**(9):2214-2223.

Beachy PA, Karhadkar SS and Berman DM (2004) Tissue repair and stem cell renewal in carcinogenesis. *Nature* **432**(7015):324-331.

Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, Salant DJ, Muller CA, Kalluri R and Zeisberg M (2010) Methylation determines fibroblast activation and fibrogenesis in the kidney. *Nat Med* **16**(5):544-550.

Bellusci S, Furuta Y, Rush MG, Henderson R, Winnier G and Hogan BL (1997) Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis. *Development* **124**(1):53-63.

Bielesz B, Sirin Y, Si H, Niranjan T, Gruenwald A, Ahn S, Kato H, Pullman J, Gessler M, Haase VH and Susztak K (2010) Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. *J Clin Invest* **120**(11):4040-4054.

Bijlsma MF, Borensztajn KS, Roelink H, Peppelenbosch MP and Spek CA (2007) Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites. *Cell Signal* **19**(12):2596-2604.

Bijlsma MF, Leenders PJ, Janssen BJ, Peppelenbosch MP, Ten Cate H and Spek CA (2008) Endogenous hedgehog expression contributes to myocardial ischemia-reperfusion-induced injury. *Exp Biol Med (Maywood)* **233**(8):989-996.

Bolanos AL, Milla CM, Lira JC, Ramirez R, Checa M, Barrera L, Garcia-Alvarez J, Carbajal V, Becerril C, Gaxiola M, Pardo A and Selman M (2012) Role of Sonic Hedgehog in idiopathic pulmonary fibrosis. *Am J Physiol Lung Cell Mol Physiol* **303**(11):L978-990.

Boor P, Ostendorf T and Floege J (2010) Renal fibrosis: novel insights into mechanisms and therapeutic targets. *Nat Rev Nephrol* **6**(11):643-656.

Bottinger EP and Bitzer M (2002) TGF-beta signaling in renal disease. *J Am Soc Nephrol* **13**(10):2600-2610.

Brennan D, Chen X, Cheng L, Mahoney M and Riobo NA (2012) Noncanonical Hedgehog signaling. *Vitam Horm* **88**:55-72.

Cain JE, Islam E, Haxho F, Chen L, Bridgewater D, Nieuwenhuis E, Hui CC and Rosenblum ND (2009) GLI3 repressor controls nephron number via regulation of Wnt11 and Ret in ureteric tip cells. *PLoS One* **4**(10):e7313.

Cain JE and Rosenblum ND (2010) Control of mammalian kidney development by the Hedgehog signaling pathway. *Pediatr Nephrol* **26**(9):1365-1371.

Caldwell S and Park SH (2009) The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. *J Gastroenterol* **44 Suppl 19**:96-101.

Chen JK, Taipale J, Cooper MK and Beachy PA (2002) Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. *Genes Dev* **16**(21):2743-2748.

Chiaramonte MG, Donaldson DD, Cheever AW and Wynn TA (1999) An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. *J Clin Invest* **104**(6):777-785.

Chinchilla P, Xiao L, Kazanietz MG and Riobo NA (2010) Hedgehog proteins activate pro-angiogenic responses in endothelial cells through non-canonical signaling pathways. *Cell Cycle* **9**(3):570-579.

Choi SS, Omenetti A, Witek RP, Moylan CA, Syn WK, Jung Y, Yang L, Sudan DL, Sicklick JK, Michelotti GA, Rojkind M and Diehl AM (2009) Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. *Am J Physiol Gastrointest Liver Physiol* **297**(6):G1093-1106.

Choi SS, Syn WK, Karaca GF, Omenetti A, Moylan CA, Witek RP, Agboola KM, Jung Y, Michelotti GA and Diehl AM (2010) Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. *J Biol Chem* **285**(47):36551-36560.

Choy SW and Cheng SH (2012) Hedgehog signaling. *Vitam Horm* **88**:1-23.

Coon DR, Roberts DJ, Loscertales M and Kradin R (2006) Differential epithelial expression of SHH and FOXF1 in usual and nonspecific interstitial pneumonia. *Exp Mol Pathol* **80**(2):119-123.

Corbit KC, Aanstad P, Singla V, Norman AR, Stainier DY and Reiter JF (2005) Vertebrate Smoothened functions at the primary cilium. *Nature* **437**(7061):1018-1021.

Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB and Liu Y (2009) Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. *J Am Soc Nephrol* **20**(9):1997-2008.

Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS and Shevde LA (2009) The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. *J Biol Chem* **284**(34):22888-22897.

Dashti M, Peppelenbosch MP and Rezaee F (2012) Hedgehog signalling as an antagonist of ageing and its associated diseases. *Bioessays* **34**(10):849-856.

De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF and Brenner DA (2008) Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. *Hepatology* **48**(6):2016-2026.

Dennler S, Andre J, Alexaki I, Li A, Magnaldo T, ten Dijke P, Wang XJ, Verrecchia F and

Mauviel A (2007) Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. *Cancer Res* **67**(14):6981-6986.

Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, Segawa T, Maeda M, Hamuro J, Nakayama T, Taniguchi M, Yagita H, Van Kaer L, Onoe K, Denhardt D, Rittling S and Uede T (2004) Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. *Immunity* **21**(4):539-550.

Ding H, Zhou D, Hao S, Zhou L, He W, Nie J, Hou FF and Liu Y (2012) Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. *J Am Soc Nephrol* **23**(5):801-813.

Drummond IA (2012) Cilia functions in development. *Curr Opin Cell Biol* **24**(1):24-30.

Eichberger T, Kaser A, Pixner C, Schmid C, Klingler S, Winklmayr M, Hauser-Kronberger C, Aberger F and Frischauf AM (2008) GLI2-specific transcriptional activation of the bone morphogenetic protein/activin antagonist follistatin in human epidermal cells. *J Biol Chem* **283**(18):12426-12437.

Eichberger T, Sander V, Schnidar H, Regl G, Kasper M, Schmid C, Plamberger S, Kaser A, Aberger F and Frischauf AM (2006) Overlapping and distinct transcriptional regulator properties of the GLI1 and GLI2 oncogenes. *Genomics* **87**(5):616-632.

Fabian SL, Penchev RR, St-Jacques B, Rao AN, Sipila P, West KA, McMahon AP and Humphreys BD (2012) Hedgehog-Gli pathway activation during kidney fibrosis. *Am J Pathol* **180**(4):1441-1453.

Fichtner-Feigl S, Strober W, Kawakami K, Puri RK and Kitani A (2006) IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. *Nat Med* **12**(1):99-106.

Fleig SV, Choi SS, Yang L, Jung Y, Omenetti A, VanDongen HM, Huang J, Sicklick JK and Diehl AM (2007) Hepatic accumulation of Hedgehog-reactive progenitors increases with severity of fatty liver damage in mice. *Lab Invest* **87**(12):1227-1239.

Fung J, Lai CL and Yuen MF (2009) Hepatitis B and C virus-related carcinogenesis. *Clin Microbiol Infect* **15**(11):964-970.

Gill PS and Rosenblum ND (2006) Control of murine kidney development by sonic hedgehog and its GLI effectors. *Cell Cycle* **5**(13):1426-1430.

Goodrich LV, Milenkovic L, Higgins KM and Scott MP (1997) Altered neural cell fates and medulloblastoma in mouse patched mutants. *Science* **277**(5329):1109-1113.

Grande MT, Fuentes-Calvo I, Arevalo M, Heredia F, Santos E, Martinez-Salgado C, Rodriguez-Puyol D, Nieto MA and Lopez-Novoa JM (2009) Deletion of H-Ras decreases renal fibrosis and myofibroblast activation following ureteral obstruction in mice. *Kidney Int* **77**(6):509-518.

Hay ED (1995) An overview of epithelio-mesenchymal transformation. *Acta Anat (Basel)* **154**(1):8-20.

He W, Dai C, Li Y, Zeng G, Monga SP and Liu Y (2009) Wnt/beta-catenin signaling promotes renal interstitial fibrosis. *J Am Soc Nephrol* **20**(4):765-776.

Hernandez-Gea V and Friedman SL (2010) Pathogenesis of liver fibrosis. *Annu Rev Pathol* **6**:425-456.

Hidalgo M and Maitra A (2009) The hedgehog pathway and pancreatic cancer. *N Engl J Med* **361**(21):2094-2096.

Horn A, Kireva T, Palumbo-Zerr K, Dees C, Tomcik M, Cordazzo C, Zerr P, Akhmetshina A, Ruat M, Distler O, Beyer C, Schett G and Distler JH (2012) Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. *Ann Rheum Dis* **71**(5):785-789.

Horn A, Palumbo K, Cordazzo C, Dees C, Akhmetshina A, Tomcik M, Zerr P, Avouac J, Gusinde J, Zwerina J, Roudaut H, Traiffort E, Ruat M, Distler O, Schett G and Distler JH (2012) Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. *Arthritis Rheum* **64**(8):2724-2733.

Huang W, Zhu G, Huang M, Lou G, Liu Y and Wang S (2010) Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. *Clin Chim Acta* **411**(9-10):675-678.

Huber MA, Kraut N and Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. *Curr Opin Cell Biol* **17**(5):548-558.

Hui CC and Angers S (2011) Gli proteins in development and disease. *Annu Rev Cell Dev Biol* **27**:513-537.

Inaguma S, Kasai K and Ikeda H (2010) GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin. *Oncogene* **30**(6):714-723.

Incardona JP, Gaffield W, Lange Y, Cooney A, Pentchev PG, Liu S, Watson JA, Kapur RP and Roelink H (2000) Cyclopamine inhibition of Sonic hedgehog signal transduction is not mediated through effects on cholesterol transport. *Dev Biol* **224**(2):440-452.

Jenkins D (2009) Hedgehog signalling: emerging evidence for non-canonical pathways. *Cell Signal* **21**(7):1023-1034.

Ji Z, Mei FC, Xie J and Cheng X (2007) Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. *J Biol Chem* **282**(19):14048-14055.

Jung IH, Jung DE, Park YN, Song SY and Park SW (2011) Aberrant Hedgehog ligands induce progressive pancreatic fibrosis by paracrine activation of myofibroblasts and ductular cells in transgenic zebrafish. *PLoS One* **6**(12):e27941.

Jung Y, Brown KD, Witek RP, Omenetti A, Yang L, Vandongen M, Milton RJ, Hines IN, Rippe RA, Spahr L, Rubbia-Brandt L and Diehl AM (2008) Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. *Gastroenterology* **134**(5):1532-1543.

Jung Y and Diehl AM (2010) Non-alcoholic steatohepatitis pathogenesis: role of repair in regulating the disease progression. *Dig Dis* **28**(1):225-228.

Jung Y, McCall SJ, Li YX and Diehl AM (2007) Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis. *Hepatology* **45**(5):1091-1096.

Jung Y, Witek RP, Syn WK, Choi SS, Omenetti A, Premont R, Guy CD and Diehl AM (2010) Signals from dying hepatocytes trigger growth of liver progenitors. *Gut* **59**(5):655-665.

Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E and Koteish A (2007) Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. *J Biol Chem* **282**(30):22089-22101.

Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM and Beachy PA (2004) Hedgehog signalling in prostate regeneration, neoplasia and metastasis. *Nature* **431**(7009):707-712.

Kasper M and Haroske G (1996) Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. *Histol Histopathol* **11**(2):463-483.

Kasper M, Regl G, Frischauf AM and Aberger F (2006) GLI transcription factors: mediators of oncogenic Hedgehog signalling. *Eur J Cancer* **42**(4):437-445.

Katoh M (2004) Human FOX gene family (Review). *Int J Oncol* **25**(5):1495-1500.

Katoh Y and Katoh M (2008) Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). *Int J Mol Med* **22**(3):271-275.

Katoh Y and Katoh M (2009) Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. *Curr Mol Med* **9**(7):873-886.

Khalil N, O'Connor RN, Flanders KC and Unruh H (1996) TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. *Am J Respir Cell Mol Biol* **14**(2):131-138.

Krauss S, Concordet JP and Ingham PW (1993) A functionally conserved homolog of the Drosophila segment polarity gene hh is expressed in tissues with polarizing activity in zebrafish embryos. *Cell* **75**(7):1431-1444.

Kusano KF, Pola R, Murayama T, Curry C, Kawamoto A, Iwakura A, Shintani S, Ii M, Asai J, Tkebuchava T, Thorne T, Takenaka H, Aikawa R, Goukassian D, von Samson P, Hamada H, Yoon YS, Silver M, Eaton E, Ma H, Heyd L, Kearney M, Munger W, Porter JA, Kishore R and Losordo DW (2005) Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. *Nat Med* **11**(11):1197-1204.

Lauth M and Toftgard R (2007) Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. *Cell Cycle* **6**(20):2458-2463.

Lavine KJ, Kovacs A and Ornitz DM (2008) Hedgehog signaling is critical for maintenance of the adult coronary vasculature in mice. *J Clin Invest* **118**(7):2404-2414.

Lazaridis KN, Strazzabosco M and Larusso NF (2004) The cholangiopathies: disorders of biliary epithelia. *Gastroenterology* **127**(5):1565-1577.

Lee UE and Friedman SL (2011) Mechanisms of hepatic fibrogenesis. *Best Pract Res Clin Gastroenterol* **25**(2):195-206.

Levine D, Rockey DC, Milner TA, Breuss JM, Fallon JT and Schnapp LM (2000) Expression of the integrin alpha8beta1 during pulmonary and hepatic fibrosis. *Am J Pathol* **156**(6):1927-1935.

Li X, Deng W, Nail CD, Bailey SK, Kraus MH, Ruppert JM and Lobo-Ruppert SM (2006) Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. *Oncogene* **25**(4):609-621.

Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, Ngan HY and Cheung AN (2009) Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. *Carcinogenesis* **30**(1):131-140.

Liu L, Kugler MC, Loomis CA, Samdani R, Zhao Z, Chen GJ, Brandt JP, Brownell I, Joyner AL, Rom WN and Munger JS (2013) Hedgehog signaling in neonatal and adult lung. *Am J Respir Cell Mol Biol* **48**(6):703-710.

Liu Y (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. *Kidney Int* **69**(2):213-217.

Lympany PA and du Bois RM (1997) Interstitial lung disease: basic mechanisms and genetic predisposition. *Monaldi Arch Chest Dis* **52**(1):33-36.

Michelotti GA, Xie G, Swiderska M, Choi SS, Karaca G, Kruger L, Premont R, Yang L, Syn WK, Metzger D and Diehl AM (2013) Smoothened is a master regulator of adult liver repair. *J Clin Invest* **123**(6):2380-2394.

Moshai EF, Wemeau-Stervinou L, Cigna N, Brayer S, Somme JM, Crestani B and Mailleux AA (2014) Targeting the hedgehog-glioma-associated oncogene homolog pathway inhibits bleomycin-induced lung fibrosis in mice. *Am J Respir Cell Mol Biol* **51**(1):11-25.

Motoyama J, Liu J, Mo R, Ding Q, Post M and Hui CC (1998) Essential function of Gli2 and Gli3 in the formation of lung, trachea and oesophagus. *Nat Genet* **20**(1):54-57.

Murone M, Rosenthal A and de Sauvage FJ (1999) Sonic hedgehog signaling by the patched-smoothened receptor complex. *Curr Biol* **9**(2):76-84.

Nagai S, Nakamura M, Yanai K, Wada J, Akiyoshi T, Nakashima H, Ohuchida K, Sato N, Tanaka M and Katano M (2008) Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. *Cancer Sci* **99**(7):1377-1384.

Neureiter D (2012) New in Hedgehog signaling: a possible role in aging, and chronic degenerative and inflammatory diseases? (Comment on DOI 10.1002/bies.201200049). *Bioessays* **34**(10):828-829.

Niu L, Wang X, Li J, Huang Y, Yang Z, Chen F, Ni H, Jin Y, Lu X and Cao Q (2007) Leptin stimulates alpha1(I) collagen expression in human hepatic stellate cells via the phosphatidylinositol 3-kinase/Akt signalling pathway. *Liver Int* **27**(9):1265-1272.

Nusslein-Volhard C and Wieschaus E (1980) Mutations affecting segment number and polarity in Drosophila. *Nature* **287**(5785):795-801.

Ochoa B, Syn WK, Delgado I, Karaca GF, Jung Y, Wang J, Zubiaga AM, Fresnedo O, Omenetti A, Zdanowicz M, Choi SS and Diehl AM (2010) Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. *Hepatology* **51**(5):1712-1723.

Omenetti A and Diehl AM (2011) Hedgehog signaling in cholangiocytes. *Curr Opin Gastroenterol* **27**(3):268-275.

Omenetti A, Popov Y, Jung Y, Choi SS, Witek RP, Yang L, Brown KD, Schuppan D and Diehl AM (2008) The hedgehog pathway regulates remodelling responses to biliary obstruction in rats.

MOL #95141

Gut **57**(9):1275-1282.

Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, Witek RP, Alpini G, Venter J, Vandongen HM, Syn WK, Baroni GS, Benedetti A, Schuppan D and Diehl AM (2008) Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. *J Clin Invest* **118**(10):3331-3342.

Omenetti A, Syn WK, Jung Y, Francis H, Porrello A, Witek RP, Choi SS, Yang L, Mayo MJ, Gershwin ME, Alpini G and Diehl AM (2009) Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. *Hepatology* **50**(2):518-527.

Omenetti A, Yang L, Li YX, McCall SJ, Jung Y, Sicklick JK, Huang J, Choi S, Suzuki A and Diehl AM (2007) Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. *Lab Invest* **87**(5):499-514.

Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz AA and Hebrok M (2006) Hedgehog/Ras interactions regulate early stages of pancreatic cancer. *Genes Dev* **20**(22):3161-3173.

Pathi S, Pagan-Westphal S, Baker DP, Garber EA, Rayhorn P, Bumcrot D, Tabin CJ, Blake Pepinsky R and Williams KP (2001) Comparative biological responses to human Sonic, Indian, and Desert hedgehog. *Mech Dev* **106**(1-2):107-117.

Pepicelli CV, Lewis PM and McMahon AP (1998) Sonic hedgehog regulates branching morphogenesis in the mammalian lung. *Curr Biol* **8**(19):1083-1086.

Pereira Tde A, Witek RP, Syn WK, Choi SS, Bradrick S, Karaca GF, Agboola KM, Jung Y, Omenetti A, Moylan CA, Yang L, Fernandez-Zapico ME, Jhaveri R, Shah VH, Pereira FE and Diehl AM (2010) Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. *Lab Invest* **90**(12):1690-1703.

Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, Moylan C, Venkatraman T, Feuerlein S, Syn WK, Jung Y, Witek RP, Choi S, Michelotti GA, Rangwala F, Merkle E, Lascola C and Diehl AM (2011) Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. *PLoS One* **6**(9):e23943.

Pinzani M, Rosselli M and Zuckermann M (2011) Liver cirrhosis. *Best Pract Res Clin Gastroenterol* **25**(2):281-290.

Pola R, Ling LE, Silver M, Corbley MJ, Kearney M, Blake Pepinsky R, Shapiro R, Taylor FR, Baker DP, Asahara T and Isner JM (2001) The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. *Nat Med* **7**(6):706-711.

Polizio AH, Chinchilla P, Chen X, Kim S, Manning DR and Riobo NA (2011) Heterotrimeric Gi

proteins link Hedgehog signaling to activation of Rho small GTPases to promote fibroblast migration. *J Biol Chem* **286**(22):19589-19596.

Pratap A, Panakanti R, Yang N, Lakshmi R, Modanlou KA, Eason JD and Mahato RI (2011) Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver: hope for marginal livers. *Mol Pharm* **8**(3):958-968.

Pratap A, Singh S, Mundra V, Yang N, Panakanti R, Eason JD and Mahato RI (2012) Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. *J Drug Target* **20**(9):770-782.

Regl G, Kasper M, Schnidar H, Eichberger T, Neill GW, Philpott MP, Esterbauer H, Hauser-Kronberger C, Frischauf AM and Aberger F (2004) Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. *Cancer Res* **64**(21):7724-7731.

Riddle RD, Johnson RL, Laufer E and Tabin C (1993) Sonic hedgehog mediates the polarizing activity of the ZPA. *Cell* **75**(7):1401-1416.

Rodriguez-Pena AB, Grande MT, Eleno N, Arevalo M, Guerrero C, Santos E and Lopez-Novoa JM (2008) Activation of Erk1/2 and Akt following unilateral ureteral obstruction. *Kidney Int* **74**(2):196-209.

Roelink H, Augsburger A, Heemskerk J, Korzh V, Norlin S, Ruiz i Altaba A, Tanabe Y, Placzek M, Edlund T, Jessell TM and et al. (1994) Floor plate and motor neuron induction by vhh-1, a vertebrate homolog of hedgehog expressed by the notochord. *Cell* **76**(4):761-775.

Rowe RG, Li XY, Hu Y, Saunders TL, Virtanen I, Garcia de Herreros A, Becker KF, Ingvarsen S, Engelholm LH, Bommer GT, Fearon ER and Weiss SJ (2009) Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. *J Cell Biol* **184**(3):399-408.

Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, Jones DE, Burt AD and Kirby JA (2008) Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. *Lab Invest* **88**(2):112-123.

Saxena NK, Titus MA, Ding X, Floyd J, Srinivasan S, Sitaraman SV and Anania FA (2004) Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. *FASEB J* **18**(13):1612-1614.

Shinozaki S, Ohnishi H, Hama K, Kita H, Yamamoto H, Osawa H, Sato K, Tamada K, Mashima H and Sugano K (2008) Indian hedgehog promotes the migration of rat activated pancreatic stellate cells by increasing membrane type-1 matrix metalloproteinase on the plasma membrane. *J Cell Physiol* **216**(1):38-46.

Sicklick JK, Li YX, Choi SS, Qi Y, Chen W, Bustamante M, Huang J, Zdanowicz M, Camp T, Torbenson MS, Rojkind M and Diehl AM (2005) Role for hedgehog signaling in hepatic stellate cell activation and viability. *Lab Invest* **85**(11):1368-1380.

Stecca B and Ruiz IAA (2010) Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. *J Mol Cell Biol* **2**(2):84-95.

Sterling JA, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, Story B, Zhao M and Mundy GR (2006) The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. *Cancer Res* **66**(15):7548-7553.

Stewart GA, Hoyne GF, Ahmad SA, Jarman E, Wallace WA, Harrison DJ, Haslett C, Lamb JR and Howie SE (2003) Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. *J Pathol* **199**(4):488-495.

St-Jacques B, Dassule HR, Karavanova I, Botchkarev VA, Li J, Danielian PS, McMahon JA, Lewis PM, Paus R and McMahon AP (1998) Sonic hedgehog signaling is essential for hair development. *Curr Biol* **8**(19):1058-1068.

Surendran K, Schiavi S and Hruska KA (2005) Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. *J Am Soc Nephrol* **16**(8):2373-2384.

Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Xie G, Philips G, Chan IS, Karaca GF, Pereira Tde A, Chen Y, Mi Z, Kuo PC, Choi SS, Guy CD, Abdelmalek MF and Diehl AM (2012) NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. *Gut* **61**(9):1323-1329.

Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, Abdelmalek MF, Guy CD, Adams DH, Kuo PC, Michelotti GA, Whitington PF and Diehl AM (2010) Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. *Hepatology* **53**(1):106-115.

Syn WK, Jung Y, Omenetti A, Abdelmalek M, Guy CD, Yang L, Wang J, Witek RP, Fearing CM, Pereira TA, Teaberry V, Choi SS, Conde-Vancells J, Karaca GF and Diehl AM (2009) Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. *Gastroenterology* **137**(4):1478-1488 e1478.

Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, Witek RP, Choi SS, Guy CD, Fearing CM, Teaberry V, Pereira FE, Adams DH and Diehl AM (2010) Accumulation of natural

killer T cells in progressive nonalcoholic fatty liver disease. *Hepatology* **51**(6):1998-2007.

Syn WK, Witek RP, Curbishley SM, Jung Y, Choi SS, Enrich B, Omenetti A, Agboola KM, Fearing CM, Tilg H, Adams DH and Diehl AM (2009) Role for hedgehog pathway in regulating growth and function of invariant NKT cells. *Eur J Immunol* **39**(7):1879-1892.

Tajiri K, Shimizu Y, Tsuneyama K and Sugiyama T (2009) Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. *Eur J Gastroenterol Hepatol* **21**(6):673-680.

Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. *Curr Opin Cell Biol* **15**(6):740-746.

Thiery JP, Acloque H, Huang RY and Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. *Cell* **139**(5):871-890.

Tseng HT, Shah R and Jamrich M (2004) Function and regulation of FoxF1 during Xenopus gut development. *Development* **131**(15):3637-3647.

Tuder RM (1996) A pathologist's approach to interstitial lung disease. *Curr Opin Pulm Med* **2**(5):357-363.

Varjosalo M and Taipale J (2008) Hedgehog: functions and mechanisms. *Genes Dev* **22**(18):2454-2472.

Walter K, Omura N, Hong SM, Griffith M, Vincent A, Borges M and Goggins M (2010) Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. *Clin Cancer Res* **16**(6):1781-1789.

Wang S, Hyun J, Youn B and Jung Y (2012) Hedgehog signaling regulates the repair response in mouse liver damaged by irradiation. *Radiat Res* **179**(1):69-75.

Weaver M, Batts L and Hogan BL (2003) Tissue interactions pattern the mesenchyme of the embryonic mouse lung. *Dev Biol* **258**(1):169-184.

Weedon MN, Lango H, Lindgren CM, Wallace C, Evans DM, Mangino M, Freathy RM, Perry JR, Stevens S, Hall AS, Samani NJ, Shields B, Prokopenko I, Farrall M, Dominiczak A, Johnson T, Bergmann S, Beckmann JS, Vollenweider P, Waterworth DM, Mooser V, Palmer CN, Morris AD, Ouwehand WH, Zhao JH, Li S, Loos RJ, Barroso I, Deloukas P, Sandhu MS, Wheeler E, Soranzo N, Inouye M, Wareham NJ, Caulfield M, Munroe PB, Hattersley AT, McCarthy MI and Frayling TM (2008) Genome-wide association analysis identifies 20 loci that influence adult height. *Nat Genet* **40**(5):575-583.

Wells RG (2008) Cellular sources of extracellular matrix in hepatic fibrosis. *Clin Liver Dis*

12(4):759-768, viii.

Witek RP, Yang L, Liu R, Jung Y, Omenetti A, Syn WK, Choi SS, Cheong Y, Fearing CM, Agboola KM, Chen W and Diehl AM (2009) Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. *Gastroenterology* **136**(1):320-330 e322.

Xie J (2005) Hedgehog signaling in prostate cancer. *Future Oncol* **1**(3):331-338.

Xie J (2008) Molecular biology of basal and squamous cell carcinomas. *Adv Exp Med Biol* **624**:241-251.

Yang L, Wang Y, Mao H, Fleig S, Omenetti A, Brown KD, Sicklick JK, Li YX and Diehl AM (2008) Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. *J Hepatol* **48**(1):98-106.

Yu J, Carroll TJ and McMahon AP (2002) Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. *Development* **129**(22):5301-5312.

Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F and Kalluri R (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. *Nat Med* **9**(7):964-968.

Zeisberg M and Neilson EG (2010) Mechanisms of tubulointerstitial fibrosis. *J Am Soc Nephrol* **21**(11):1819-1834.

Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, Xie H, Wang J, Han Y, Liu Z and Fan D (2008) Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. *Int J Clin Pract* **62**(7):1056-1062.

Zhao M, Qiao M, Harris SE, Chen D, Oyajobi BO and Mundy GR (2006) The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. *Mol Cell Biol* **26**(16):6197-6208.

MOL #95141

FOOTNOTES

FIGURES

Figure 1. Hh signaling in vertebrates. (A) In the absence of Hh ligand (eg. Shh), Ptch inhibits Smo from reaching the plasma membrane, and thus the microtubule-associated Cos2-Fu-SuFu complex can bind full length Gli, which can be phosphorylated by Glycogen Synthase Kinase 3β (GSK3β), Protein Kinase A (PKA), and Casein Kinase 1 (CK1). Phosphorylated Gli is cleaved to an N-terminal form, and then translocates the nucleus to suppress transcription. (B) In the presence of Hh ligand, Ptch activity is suppressed, and thereby Smo translocates to the plasma membrane and interacts with Cos2. In this state, the Cos2-Fu-SuFu complex can not bind Gli, and Gli is able to enter the nucleus and induce transcription of target genes. This figure is based on previously published illustrations (Gill and Rosenblum, 2006).

Figure 2. Two types of noncanonical Hh signaling. Type I requires only binding of an Hh isoform to Ptch and is mediated by novel functions of Ptch unrelated to Smo repression, and it is by definition insensitive to Smo modulators. Type II is dependent on Smo and in some cases it has been shown to rely on signaling through Gli proteins, and it is both mimicked by Smo agonists and inhibited by Smo antagonists. This figure is based on previously published illustrations (Brennan et al., 2012).

Figure 3. Activation of Hh signaling promotes the myofibroblast phenotypes in many types of tissues.

Figure 1

Figure 2

Type I : Hh-dependent cyclopamine-insensitive cellular responses

Type II : Hh-dependent mimicked by Smo agonists cyclopamine-sensitive cellular responses

Figure 3